A Randomized Double Blind Phase II trial of Surgery, Radiation Therapy plus Temozolomide and Pembrolizumab with and without HSPPC-96 in patients with newly diagnosed Glioblastoma (GBM)

Start Date: February 19, 2019

IRB Number: https://clinicaltrials.gov/ct2/show/NCT03018288

Condition/Disease: Cancer - Brain

Principal Investigator: Tobias Walbert, MD

Purpose of Research:

Radiation Therapy, Temozolomide, Pembrolizumab, HSPPC-96, Glioblastoma

Status: Accepting Participants

Phone: (313) 916-1784

Filter Results